Alnylam reports hemophilia, PNH interim data

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) fell $11.24 (10%) to $97.72 on Monday after it reported interim data from a Phase I study of fitusiran ( ALN-AT3) to treat hemophilia A and B and a Phase I/II dose-ranging study of ALN-CC5 to treat paroxysmal nocturnal hemoglobinuria.

Alnylam said the most effective weekly dose of fitusiran, 45 ug/kg, reduced antithrombin levels by a mean maximum of 55% and maximum of 86% in six patients. With monthly dosing, 900 ug/kg lowered antithrombin levels to a mean maximum of 78% and maximum of 88% in three patients. ...